Axon Enterprise
AXON
$547.03
-3.32%
Axon Enterprise is building a public safety operating system by integrating hardware devices like TASER energy weapons and body cameras with cloud-based digital evidence management software. As a dominant player in the law enforcement technology space, it holds a unique competitive position by combining hardware and software into a recurring revenue model. The current investor narrative centers on Axon's AI and drone-driven growth acceleration, with recent earnings beats and raised guidance highlighting strong demand, though the stock remains over 50% below its 52-week high amid broader market volatility.…
AXON
Axon Enterprise
$547.03
Related headlines
Investment Opinion: Should I buy AXON Today?
Rating: Hold. Axon is a high-growth company with accelerating revenue and positive free cash flow, but its extreme valuation (trailing P/E 355x) and recent earnings collapse warrant caution. The analyst consensus is bullish with an average EPS estimate of $13.89, implying a forward P/E of 53.5x, which is still a significant premium to the industry.
Supporting Evidence: Revenue grew 38.5% YoY to $796.7M in Q4 2025, the highest quarterly revenue ever. Gross margin is healthy at 57.9%, though down from 60.1% in Q3. Free cash flow turned positive at $155.4M in Q4, a strong improvement. The forward P/E of 53.5x is high but could compress if the company delivers on EPS estimates of $13.89. The stock has strong relative strength (+52.4% vs SPY over 3 months) and analyst support.
Risks & Conditions: The biggest risks are margin compression (net income fell 97.8% YoY) and valuation multiple compression if growth slows. This Hold would upgrade to Buy if the forward P/E compresses below 35x or if operating margins consistently exceed 10%. It would downgrade to Sell if revenue growth decelerates below 20% or if free cash flow turns negative again. Overall, Axon is overvalued relative to its trailing earnings but fairly valued on forward estimates if growth materializes.
Sign up to view all
AXON 12-Month Price Forecast
Axon's growth story is compelling, with revenue accelerating and free cash flow improving. However, the extreme trailing valuation and collapsing net income create significant risk. The AI stance is neutral because the bull case (sustained growth, margin expansion) and bear case (deceleration, multiple compression) are both plausible. The key factor to watch is operating margin: if it expands above 5%, the stock could re-rate higher; if it stays below 2%, the valuation will likely compress. The analyst consensus is bullish, but the wide range of EPS estimates ($5.73 to $18.14) highlights uncertainty. I would upgrade to bullish if operating margins exceed 8% for two consecutive quarters, and downgrade to bearish if revenue growth falls below 20%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Axon Enterprise's 12-month outlook, with a consensus price target around $711.14 and implied upside of +30.0% versus the current price.
Average Target
$711.14
10 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
10
covering this stock
Price Range
$438 - $711
Analyst target range
Axon is covered by 10 analysts, with a consensus leaning bullish: ratings include Outperform/Overweight from RBC Capital, Barclays, Piper Sandler, and Morgan Stanley, and a Neutral from UBS. The average estimated EPS for the next fiscal year is $13.89, with a low of $5.73 and high of $18.14. The average revenue estimate is $6.08 billion, implying significant growth from the current run rate. The implied upside to the average target is not directly calculable without a price target, but the strong EPS estimates suggest analysts expect substantial earnings growth. The target range for EPS is wide ($5.73 to $18.14), indicating high uncertainty about the pace of margin expansion. The low end may reflect concerns about competitive pressure or slower adoption, while the high end assumes accelerating AI/drone sales and operating leverage. Recent ratings have been reaffirmed, with no downgrades, suggesting analyst conviction remains positive despite the stock's decline from highs.
Drowning in data?
Find the real signal!
Bulls vs Bears: AXON Investment Factors
Axon presents a classic high-growth, high-valuation debate. On the bull side, revenue is accelerating at 38.5% YoY, free cash flow has turned positive, and analyst sentiment remains bullish with strong EPS growth expectations. On the bear side, the trailing P/E of 355x is extreme, net income has collapsed, and the stock is still down 22.8% over the past year despite a recent bounce. The single most important tension is whether Axon can translate its revenue growth into sustainable profitability: if margins expand as operating leverage kicks in, the forward P/E of 53.5x could prove justified; if not, the stock faces severe multiple compression. Currently, the bull case has stronger evidence given the accelerating revenue and positive FCF, but the valuation leaves little room for error.
Bullish
- Revenue accelerating 38.5% YoY: Q4 2025 revenue hit $796.7M, up 38.5% year-over-year and accelerating from $710.6M in Q3 2025. This marks the highest quarterly revenue in the dataset, driven by strong demand for TASER devices, body cameras, and cloud software.
- Recurring software revenue growing: Software and Sensors segment contributed $305.2M in Q4 2025, indicating a growing mix of higher-margin recurring revenue. This recurring base provides visibility and supports margin expansion over time.
- Free cash flow turned positive: Free cash flow was $155.4M in Q4 2025, a significant improvement from negative FCF in Q2 2025. Strong cash generation supports internal funding of growth initiatives without dilutive equity raises.
- Analyst consensus bullish with upside: 10 analysts cover AXON with ratings like Outperform from RBC, Barclays, Piper Sandler, and Morgan Stanley. Average EPS estimate for next fiscal year is $13.89, implying a forward P/E of 53.5x, which could compress if earnings materialize.
Bearish
- Extreme trailing P/E of 355x: Trailing P/E of 354.96x is near the top of its historical range (32x to 3800x). This leaves no room for error; any earnings miss could trigger severe multiple compression.
- Net income collapsed in Q4 2025: Net income fell to $3.0M in Q4 2025 from $135.2M in Q4 2024, a 97.8% decline. Despite revenue growth, profitability has deteriorated sharply, raising concerns about cost control and operating leverage.
- Stock down 22.8% over 1 year: Despite the recent rally, AXON is still down 22.8% over the past year, underperforming SPY's +20.6% gain. The 52-week high of $885.92 remains a major resistance level.
- High valuation vs industry peers: Forward P/E of 53.5x is a 114% premium to the Aerospace & Defense industry average of ~25x. While growth justifies some premium, the magnitude leaves the stock vulnerable to sector rotation or growth disappointments.
AXON Technical Analysis
The stock is in a sharp downtrend over the past year, with a 1-year price change of -22.81%, and currently trades at $565.80, which is 63.9% of its 52-week range (low $339.01, high $885.92). This positioning near the lower end of the range suggests the stock is deeply oversold, but also reflects persistent selling pressure and a lack of sustained buying interest. The 1-month price change of +26.41% shows a strong short-term bounce, while the 3-month change of +63.55% indicates a powerful recovery from the April lows near $345. This recent momentum diverges sharply from the negative 1-year trend, potentially signaling a trend reversal or a mean-reversion rally. The relative strength versus SPY is +22.34% over 1 month and +52.44% over 3 months, confirming that Axon is outperforming the market in the near term. The 52-week high of $885.92 acts as major resistance, while the 52-week low of $339.01 provides support. A breakout above $885.92 would signal a resumption of the prior uptrend, while a breakdown below $339.01 could lead to further downside. With a beta of 1.378, Axon is 37.8% more volatile than the S&P 500, meaning larger swings in both directions, which is critical for risk management.
Beta
1.38
1.38x market volatility
Max Drawdown
-60.3%
Largest decline past year
52-Week Range
$339-$886
Price range past year
Annual Return
-25.0%
Cumulative gain past year
| Period | AXON Return | S&P 500 |
|---|---|---|
| 1m | +23.8% | +1.0% |
| 3m | +43.6% | +7.9% |
| 6m | -13.1% | +8.5% |
| 1y | -25.0% | +20.1% |
| ytd | -2.9% | +9.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AXON Fundamental Analysis
Revenue grew 38.53% year-over-year to $796.7 million in Q4 2025, accelerating from the prior quarter's $710.6 million and marking the highest quarterly revenue in the data set. The multi-quarter trend shows consistent growth from $459.9 million in Q1 2024 to $796.7 million in Q4 2025, driven by strong demand for both connected devices (TASER, cameras) and software/services. The Software and Sensors segment contributed $305.2 million in the most recent period, indicating a growing mix of higher-margin recurring revenue. Net income was $3.0 million in Q4 2025, a sharp decline from $135.2 million in Q4 2024, but the company remains profitable on a trailing basis. Gross margin was 57.9% in Q4 2025, slightly down from 60.1% in Q3 2025, but still healthy. Operating margin turned positive at 1.26% in Q4 2025, improving from negative margins earlier in the year, suggesting operating leverage is beginning to materialize. The company has a current ratio of 2.53 and a debt-to-equity ratio of 0.59, indicating a solid liquidity position and manageable leverage. Free cash flow was $155.4 million in Q4 2025, a significant improvement from negative free cash flow in Q2 2025, and ROE stands at 3.85%, reflecting modest profitability relative to equity. The strong free cash flow generation supports internal funding of growth initiatives.
Quarterly Revenue
$796724000.0B
2025-12
Revenue YoY Growth
+38.5%
YoY Comparison
Gross Margin
57.9%
Latest Quarter
Free Cash Flow
$75081000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AXON Overvalued?
Since net income is positive (TTM net income of $3.0 million), the primary valuation metric is the P/E ratio. The trailing P/E is 354.96x, while the forward P/E is 53.51x, implying the market expects a dramatic earnings improvement. The wide gap between trailing and forward P/E suggests aggressive growth expectations baked into the stock. Compared to the Aerospace & Defense industry average P/E of approximately 25x (based on sector data), Axon's forward P/E of 53.51x represents a 114% premium. This premium may be justified by Axon's superior revenue growth (38.5% YoY) and its unique position in the public safety technology niche, but it also leaves little room for error. Historically, Axon's trailing P/E has ranged from 32x (Q2 2022) to over 3800x (Q4 2025), with the current 355x near the top of its historical band. This indicates the market is pricing in optimistic future earnings, and any disappointment could lead to multiple compression.
PE
355.0x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -6436x~3805x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
236.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Axon's net income collapsed to $3.0M in Q4 2025 from $135.2M a year earlier, a 97.8% decline, despite revenue growing 38.5%. This suggests cost growth is outpacing revenue, with operating expenses rising sharply (R&D alone was $134M in Q4). The company has a debt-to-equity ratio of 0.59, which is manageable, but the current ratio of 2.53 indicates ample liquidity. However, the reliance on continued high growth to justify the 355x trailing P/E means any deceleration could trigger a severe valuation reset. Free cash flow turned positive at $155.4M in Q4, but the TTM FCF of $75.1M is still modest relative to the $45.7B market cap.
Market & Competitive Risks: Axon trades at a forward P/E of 53.5x, a 114% premium to the Aerospace & Defense industry average of ~25x. This premium makes it vulnerable to valuation compression if growth slows or if the market rotates away from growth stocks. With a beta of 1.378, the stock is 37.8% more volatile than the S&P 500, amplifying downside in market selloffs. Competitive risks include potential entrants in public safety technology, though Axon's integrated hardware-software ecosystem provides a moat. Recent news highlights privacy concerns around facial recognition, which could lead to regulatory headwinds for Axon's AI and drone products.
Worst-Case Scenario: If revenue growth decelerates below 20% and margins fail to expand, the stock could re-rate to a forward P/E more in line with the industry average of 25x. Applying that to the average EPS estimate of $13.89 gives a price of ~$347, near the 52-week low of $339.01. From the current price of $565.80, this implies a potential downside of -38.6%. In a severe recession or regulatory crackdown, the stock could fall to the 52-week low of $339.01, representing a -40.1% loss from current levels.
FAQ
The primary risk is valuation: a trailing P/E of 355x leaves no room for error. Second, net income collapsed 97.8% YoY in Q4 2025, indicating poor operating leverage. Third, the stock has a beta of 1.378, making it 37.8% more volatile than the market. Fourth, regulatory risks around AI and drone technology could impact growth. The most severe risk is a growth deceleration below 20%, which could trigger a re-rating to a forward P/E of 30x, implying a stock price near $340 (the 52-week low).
The 12-month outlook is mixed. The bull case (30% probability) sees the stock reaching $700-885 driven by sustained 30%+ growth and margin expansion. The base case (45% probability) expects $500-700 as growth moderates to 25% and margins improve gradually. The bear case (25% probability) targets $340-500 if growth decelerates below 20% and multiple compression occurs. The most likely scenario is the base case, assuming revenue growth of 25% and operating margins of 5-8%. The wide range of analyst EPS estimates ($5.73 to $18.14) highlights uncertainty.
Axon is overvalued on trailing earnings (P/E 355x) but fairly valued on forward estimates (P/E 53.5x) if the company delivers on EPS of $13.89. Compared to the Aerospace & Defense industry average P/E of 25x, AXON trades at a 114% premium. Historically, its trailing P/E has ranged from 32x to over 3800x, so the current 355x is near the high end. The market is pricing in aggressive future growth and margin expansion. If the company fails to deliver, the stock could see significant multiple compression.
Axon is a high-growth stock with accelerating revenue (38.5% YoY) and positive free cash flow, but it carries extreme valuation risk (trailing P/E 355x). The analyst consensus is bullish, with an average EPS estimate of $13.89 for next year, implying a forward P/E of 53.5x. The biggest downside risk is margin compression: net income fell 97.8% YoY in Q4 2025. For long-term growth investors with high risk tolerance, it could be a good buy if you believe margins will expand; for value-conscious investors, it is overvalued. A better entry point might be if the stock pulls back to the $400-450 range, closer to its 52-week low.
Axon is better suited for long-term investment (3-5 years) given its high growth and recurring revenue model, but it requires high risk tolerance due to extreme volatility (beta 1.378). Short-term trading is risky because the stock has a short ratio of 3.35 and is down 22.8% over the past year despite a recent rally. The company pays no dividend, so returns depend entirely on price appreciation. A minimum holding period of 3 years is recommended to allow the growth story to play out. For short-term traders, the stock's high beta offers opportunities but also significant downside risk.
